

1 **Infliximab for Treatment of Adults Hospitalized with Moderate or Severe Covid-19**

2

3 Jane A. O'Halloran, Eyal Kedar, Kevin J. Anstrom, Matthew W. McCarthy, Emily R. Ko, Patricia
4 Segura Nunez, Cynthia Boucher, P. Brian Smith, Reynold A. Panettieri, Jr, Sabina Mendivil
5 Tuchia de Tai, Martin Maillo, Akram Khan, Alfredo J. Mena Lora, Matthias Salathe, Gerardo
6 Capo, Daniel Rodríguez Gonzalez, Thomas F. Patterson, Christopher Palma, Horacio Ariza,
7 Maria Patelli Lima, Anne M. Lachiewicz, John Blamoun, Esteban C. Nannini, Eduardo Sprinz,
8 Analia Mykietiuk, Radica Alicic, Adriana M. Rauseo, Cameron R. Wolfe, Britta Witting, Daniel K.
9 Benjamin, Jr, Steven E. McNulty, Pearl Zakrofsky, Susan Halabi, Sandra Butler, Jane Atkinson,
10 Stacey J. Adam, Richard Melsheimer, Soju Chang, Lisa LaVange, Michael Proschan, Samuel
11 A. Bozzette, William G. Powderly for the ACTIV-1 IM study group members*

12 *Author degrees and affiliations are listed at the end of the article.

13

14 **Running title:** Infliximab for hospitalized Covid-19

15 **Word count:** 2699

16 **Address for correspondence:** William G. Powderly, MD, Division of Infectious Diseases,
17 Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110.

18 Email: Wpowderly@wustl.edu.

19

20 **ABSTRACT**

21 **Background:** Immune dysregulation contributes to poorer outcomes in severe Covid-19.

22 Immunomodulators targeting various pathways have improved outcomes. We investigated
23 whether infliximab provides benefit over standard of care.

24 **Methods:** We conducted a master protocol investigating immunomodulators for potential benefit
25 in treatment of participants hospitalized with Covid-19 pneumonia. We report results for
26 infliximab (single dose infusion) versus shared placebo both with standard of care. Primary
27 outcome was time to recovery by day 29 (28 days after randomization). Key secondary
28 endpoints included 14-day clinical status and 28-day mortality.

29 **Results:** A total of 1033 participants received study drug (517 infliximab, 516 placebo). Mean
30 age was 54.8 years, 60.3% were male, 48.6% Hispanic or Latino, and 14% Black. No
31 statistically significant difference in the primary endpoint was seen with infliximab compared with
32 placebo (recovery rate ratio 1.13, 95% CI 0.99–1.29; p=0.063). Median (IQR) time to recovery
33 was 8 days (7, 9) for infliximab and 9 days (8, 10) for placebo. Participants assigned to
34 infliximab were more likely to have an improved clinical status at day 14 (OR 1.32, 95% CI
35 1.05–1.66). Twenty-eight-day mortality was 10.1% with infliximab versus 14.5% with placebo,
36 with 41% lower odds of dying in those receiving infliximab (OR 0.59, 95% CI 0.39–0.90). No
37 differences in risk of serious adverse events including secondary infections.

38 **Conclusions:** Infliximab did not demonstrate statistically significant improvement in time to
39 recovery. It was associated with improved 14-day clinical status and substantial reduction in 28-
40 day mortality compared with standard of care.

41 **Trial registration:** ClinicalTrials.gov (NCT04593940).

42 **Keywords:** infliximab, immune modulators, COVID-19, master protocol, shared placebo, TNF
43 alpha inhibitors

44

45 **INTRODUCTION**

46 Immune dysregulation induced by severe acute respiratory syndrome coronavirus-2 (SARS-
47 CoV-2) is a major cause of morbidity and mortality.¹ While treatments directly targeting SARS-
48 CoV-2 have shown significant impact in earlier stages of Covid-19,² immunomodulating agents
49 provide benefit in hypoxia observed in later disease stages.³⁻⁶

50 Tumor necrosis factor alpha (TNF) is a pro-inflammatory cytokine that plays a role in
51 nearly all acute inflammatory reactions.⁷ In patients hospitalized for Covid-19, increased TNF
52 levels are associated with more severe disease and death.⁸ Inhibition of TNF reduces disease
53 severity in mouse models of other respiratory viruses.⁹ Infliximab, a TNF inhibitor that binds both
54 soluble and transmembrane forms of TNF, is approved and commonly used to treat
55 autoimmune diseases, including inflammatory bowel disease and rheumatoid arthritis.
56 Data on infliximab use in Covid-19 treatment is limited.¹⁰⁻¹² However, patients who developed
57 Covid-19 while on TNF inhibitors for other indications did not experience adverse outcomes.^{13,14}

58 In April 2020, the National Institutes of Health (NIH) launched a public-private
59 partnership, Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV), to develop
60 a coordinated research response to Covid-19. ACTIV-1 IM was a master protocol designed to
61 evaluate immunomodulatory agents in hospitalized patients with moderate/severe Covid-19.
62 Infliximab was one of the agents included in ACTIV-1 IM based on its mechanism of action and
63 efficacy and safety profile in inflammatory disorders. We report the results of a randomized,
64 double-blind, placebo-controlled evaluation of infliximab compared with placebo in addition to
65 standard of care.

66

67 **METHODS**

68 **Study design**

69 The ACTIV-1 IM master protocol was developed to allow for parallel investigation of efficacy and
70 safety of multiple immunomodulators compared with a shared placebo, with standard of care

71 given as background therapy in both arms. Remdesivir (Gilead Sciences, Foster City, CA) was
72 provided as standard of care and given to eligible participants.

73

74 **Eligibility**

75 Eligibility criteria are outlined in the **Supplementary Appendix**. Briefly, adults ≥ 18 years with
76 confirmed moderate/severe SARS-CoV-2 infection admitted to hospital were eligible.

77 Radiological evidence of pulmonary involvement or oxygen saturation $\leq 94\%$ on room air or
78 supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation

79 (ECMO) was required. Exclusion criteria included aspartate aminotransferase or alanine

80 aminotransferase > 10 times the upper limit of normal, estimated glomerular filtration rate < 30

81 mL/min, history of New York Heart Association class III/IV congestive heart failure, neutropenia,

82 lymphopenia, targeted immune therapies for any indication in the last four weeks or five drug

83 half-lives, or evidence of untreated tuberculosis or other untreated infections. Participants were

84 excluded from the infliximab substudy if they had a history of hepatosplenic T-cell lymphoma or

85 other lymphoma within five years before screening, history of or current diagnosis of multiple

86 sclerosis or other significant demyelinating condition.

87 Eligible participants were randomized in a two-stage process (**Supplementary**

88 **Appendix**). Between October 16, 2020, and December 31, 2021, 1061 participants were

89 randomized at 69 sites across five countries. Infliximab was administered on day 1 as a single-

90 dose intravenous infusion of 5 mg/kg over at least 2 hours. All participants received local

91 standard of care.

92

93 **Procedures**

94 Participants' clinical status was captured daily through day 29 if hospitalized. For discharged

95 participants, clinical status was assessed on days 8, 11, 15, and 29 in-person or by telephone if

96 in-person assessment was not possible. Day 60 follow-up was conducted by telephone
97 **(Supplementary Appendix).**

98

99 **Outcomes and statistical analysis**

100 The primary outcome was time to recovery evaluated up to day 29 (for clinical status on day
101 28). Recovery was defined as the first day on which participants attained category 6, 7, or 8 on
102 the 8-point ordinal scale (OS) defined in **Supplementary Appendix**. The primary efficacy
103 analysis was based on the Fine-Gray model with stratification by region and baseline disease
104 severity.¹⁵

105 Key secondary outcomes were mortality and clinical status assessed by 8-point OS at
106 days 14 and 28. Logistic and ordinal logistic regression models were used to estimate treatment
107 effects for mortality and 8-point OS endpoints. A multiple imputation approach was used to
108 account for the small amount of missing data for key secondary endpoints (**Statistical Analysis**
109 **Plan [SAP]**). The gatekeeping approach for controlling Type I error for the primary endpoint,
110 day 14 clinical status, and day 28 mortality is described in the SAP, including relevant p-value
111 cutoffs (**Table S1**).

112 Safety assessments included a composite endpoint of death, serious adverse events
113 (SAEs), or grade 3 (severe) and 4 (potentially life-threatening) AEs occurring through day 60.
114 Secondary infections as AEs of special interest through day 60 and discontinuation or
115 temporary suspension of trial-product administration for any reason were also assessed.

116 All efficacy and safety analyses reported are based on the modified intention-to-treat
117 (mITT) population consisting of all randomized participants who received at least one dose of
118 assigned study drug (infliximab or shared placebo), limiting shared placebo participants to those
119 eligible for infliximab.

120

121 **RESULTS**

122 **Participants**

123 Of 1061 participants who underwent randomization in this substudy, 531 were assigned to the
124 infliximab group and 530 to the shared placebo group (**Figure S1**). Ultimately, 517 participants
125 in the infliximab group and 516 in the shared placebo group received at least one dose of
126 assigned treatment and constitute the mITT population. Consistent with the protocol-specified
127 mITT definition, four participants were excluded post-randomization because they received
128 incorrect study drug. At baseline, 578 (56.0%) participants had moderate disease (52.1% and
129 3.9% OS 4 and 5) and 455 (44.0%) had severe disease (10.7% and 33.3% OS 2 and 3). Study
130 discontinuation by day 29 occurred in 4.8% in the infliximab group and 4.5% in the shared
131 placebo group. Mean age was 54.8 years and 60% were male. Overall, 652 (63.1%) were
132 White, 145 (14.0%) Black, 27 (2.6%) Asian, and 9 (0.9%) American Indian or Alaska Native; 502
133 (48.6%) were Hispanic or Latino. Overall, 975 (94.4%) participants received remdesivir, while
134 950 (92.0%) received corticosteroids (**Table 1**). Characteristics by region are shown in **Table**
135 **S2, S3**.

136

137 **Primary outcome**

138 Median time to recovery for infliximab was 1 day shorter than with shared placebo, but the
139 difference did not reach statistical significance (median 8 vs. 9 days; recovery rate ratio [RRR]
140 1.13, 95% confidence interval [CI] 0.99–1.29; $p=0.063$) (**Table 2, Figure S2**). Across OS
141 subgroups, the interaction p -value was 0.36 indicating no difference. Median time to recovery
142 among participants receiving mechanical ventilation/ECMO at enrollment (OS 2) was 23 days
143 for infliximab and >28 for shared placebo (RRR 1.117, 95% CI 0.612–2.039). For those on
144 noninvasive ventilation or high-flow oxygen (OS 3), median time to recovery was 11 days for
145 infliximab and 13 for shared placebo (RRR 1.326, 95% CI 1.039–1.693). Among those
146 hospitalized requiring supplemental oxygen (OS 4) and those hospitalized not requiring oxygen

147 (OS 5), median time to recovery was 6 versus 7 days (RRR 1.090, 95% CI 0.923–1.286) and 5
148 versus 4 days (RRR 0.767, 95% CI 0.404–1.455) (**Table 2**).

149

150 **Key secondary outcomes**

151 ***Mortality***

152 Mortality at day 28 was 10.1% for infliximab and 14.5% for shared placebo (odds ratio [OR] for
153 death 0.59, 95% CI 0.39–0.90), resulting in 41% lower adjusted odds of dying (**Table 2, Figures**
154 **1, 2A**). When 28-day mortality was examined by OS, the interaction p-value was 0.31 indicating
155 no difference across subgroups. No difference in mortality was observed in the most severe
156 disease (OS 2) (OR 1.11, 95% CI 0.45–2.72) (**Figure 2C**). However, mortality decreased in
157 those who received infliximab compared with placebo for OS 3 (OR 0.52, 95% CI 0.29–0.91)
158 and OS 4/5 (OR 0.47, 95% CI 0.20–1.13). (**Figure 2D, E**) No deaths occurred in the OS 5
159 group. Day 14 mortality was 5.6% for infliximab and 8.1% for shared placebo (OR 0.63, 95% CI
160 0.36–1.08). Additional analysis revealed 60-day mortality rates of 12.6% in the infliximab group
161 and 16.5% in the shared placebo group, with a 32% reduction of odds of mortality observed (OR
162 0.68, 95% CI 0.46–0.999). The vast majority of those who died between day 29 and 60 were
163 intubated at day 28. In subgroup analyses, although point estimates indicated benefit for
164 infliximab in both c-reactive protein (CRP) subgroups, there was a trend for a stronger mortality
165 reduction at 28 days in participants with CRP >75 mg/L at baseline compared with CRP ≤75
166 mg/L.

167

168 ***Clinical status***

169 The odds of improvement in clinical status at day 14 and day 28, as assessed by the OS, were
170 greater with infliximab compared with shared placebo (OR for improvement 1.32, 95% CI 1.05–
171 1.66) and (1.45 95% CI 1.14–1.85) **Tables 2 & S4, Figure S3**. For day 14, the interaction p-
172 value for subgroup analysis by OS was 0.90. On day 14, clinical status was improved with

173 infliximab compared with shared placebo for those at OS 2, 3, and 4 at randomization with the
174 strongest effect in OS 3 (OR 1.48, 95% CI 1.01–2.17). No difference was observed for OS 5. All
175 intention-to-treat data are presented in **Tables S5 and S6**.

176

177 **Safety Assessments**

178 No difference was observed in the composite safety endpoint at day 60 (32.9% vs. 33.7%;
179 hazard ratio [HR] 0.96, 95% CI 0.78–1.19). The number of participants with one or more grade 3
180 or 4 AEs was similar, (infliximab 146 [28.2%], shared placebo 131 [25.4%], risk difference 2.9;
181 95% CI -2.6 to 8.3) (**Table 3**). SAEs occurred in 125 (24.2%) participants in the infliximab group,
182 with seven events in six participants (1.2%), assessed by investigators as infliximab-related.
183 SAEs occurred in 130 (25.2%) participants in the control group, and the events were attributed
184 to trial product in seven of these participants (1.4%). One participant experienced grade 1 (mild)
185 infusion reaction in the infliximab group.

186 The percentage of participants who had any secondary infection was similar at day 60
187 with infliximab and shared placebo (79 [15.3%] vs. 72 [14.0%]) (**Table 3**). The most common
188 secondary infections were bacterial pneumonia, bloodstream and urinary tract infections (**Table**
189 **3**). All secondary infections were adjudicated by an independent safety officer.

190

191 **DISCUSSION**

192 This randomized, double-blind, placebo-controlled trial evaluated the addition of infliximab to
193 standard of care in hospitalized participants with moderate-to-severe Covid-19 pneumonia. The
194 trial displayed a strong, but not statistically significant, improvement in the primary endpoint of
195 time to recovery. We did, however, observe substantial improvements for key secondary
196 endpoints of 28-day mortality and 14-day clinical status. Infliximab was associated with a 41%
197 lower adjusted odds of death at 28 days in participants hospitalized with Covid-19. The mortality
198 benefit was observed across age groups, sexes, and races/ethnicities. Analysis demonstrated

199 that this mortality benefit was maintained to the completion of study at 60 days. Although some
200 additional deaths occurred after day 28 in both groups, these were mainly in participants
201 intubated at day 28. Sub-analysis by OS showed infliximab, when added to standard of care,
202 reduced mortality across a spectrum of disease severity with hospitalized participants requiring
203 supplemental oxygen and those on high-flow oxygen devices benefiting. In contrast, we
204 observed no benefit in those on mechanical ventilation or ECMO or those not requiring
205 supplemental oxygen. In another subgroup analysis, a stronger mortality benefit was observed
206 with the addition of infliximab to standard of care in participants with CRP >75mg/L at baseline
207 compared with those with CRP ≤75 mg/L.

208 Identification of anti-inflammatory agents to prevent or reverse dysregulated immune
209 cascades characteristic of severe Covid-19 has are an important area of investigation. The
210 addition of dexamethasone was shown to improve survival in patients requiring supplemental
211 oxygen and became embedded in standard of care.³ However, the high morbidity and mortality
212 of Covid-19 and heterogeneity of therapeutic responses suggested the need for additional
213 immunomodulators. The JAK1/JAK2 inhibitor, baricitinib, and IL-6 antibody, tocilizumab, have
214 shown benefit for patients particularly in the setting of progressive respiratory failure.^{4,6,16,17}
215 Results from these trials prompted the NIH guidelines panel to recommend tocilizumab or
216 baricitinib as a second immunomodulator in addition to dexamethasone for patients with
217 progressive respiratory failure and evidence of systemic inflammation.¹⁸

218 The infliximab data reported here, and a parallel report of the study of abatacept from
219 ACTIV-1 IM, adds to our knowledge by demonstrating mortality benefit for two separate
220 immunomodulators with unique and different mechanisms of action. Taken together with prior
221 studies, we now have substantial evidence that additional immunomodulation added to
222 corticosteroids reduces mortality and improves clinical outcomes in hospitalized patients with
223 moderate/severe Covid-19. The fact that this occurs with a variety of immunomodulatory agents,

224 all with different targets, is particularly interesting and establishing a better understanding of this
225 synergy is warranted at a mechanistic level.

226 Infliximab, in particular, and TNF blockade, in general, may be beneficial in Covid-19
227 management where elevated cytokine levels are seen in severe disease. TNF activates a wide
228 variety of immune cells and aberrant TNF-signaling is a central feature of cytokine release
229 syndrome.¹⁹ One concern with TNF blockade in the setting of any viral illness is secondary
230 infection. Encouragingly, there were no new or negative safety signals observed during this trial,
231 including no differences between the infliximab and placebo groups in secondary infections.
232 These observations are consistent with infliximab's known safety profile having been used in the
233 treatment of inflammatory diseases for over twenty years. Likewise, the simplicity of a single
234 infusion and the global availability of infliximab could potentially increase the arsenal of
235 therapies available for treatment of moderate/severe Covid-19 in settings where current
236 guideline recommended therapies are not widely available.

237 With each completed trial we gain greater understanding of Covid-19, although
238 numerous clinical questions remain. In particular, there is lack of clarity around the optimal
239 management of patients requiring low-flow oxygen when first hospitalized. Subgroup analyses
240 presented here begin to address this. We show an apparent mortality benefit for
241 immunomodulators in both moderate and severe illness. Our results for participants with
242 moderate disease show improvement independent of inflammatory markers or clinical factors,
243 suggesting treatment with infliximab early in the disease process could provide benefit. In
244 contrast, our data do not support the addition of infliximab to dexamethasone in patients already
245 requiring mechanical ventilation. Additionally, subgroup analysis suggested a greater benefit in
246 both time to recovery and mortality in participants with CRP >75mg/L, suggesting patients with
247 evidence of more severe systemic inflammation at presentation to hospital may benefit more
248 from the addition of a second agent, such as infliximab, to dexamethasone. Future studies

249 should examine if a biomarker-driven approach facilitates early identification of people at-risk for
250 progression who could benefit from additional immunomodulation.

251 A limitation of this study is that the primary endpoint did not reach statistical significance.
252 Therefore, based on the pre-defined gatekeeping approach, the key secondary endpoints of 28-
253 day mortality and day 14 clinical status are not considered statistically significant although very
254 clinically relevant. A major challenge for this and other studies during the pandemic was the
255 appropriate selection of a primary endpoint in the setting of rapidly changing clinical scenarios.²⁰
256 While a mortality primary endpoint is sometimes considered definitive and lacking in subjectivity,
257 it can require large participant numbers and potentially result in prolonged study recruitment and
258 delayed results. In addition, mortality does not encompass other patient-centered outcomes
259 which are a greater focus in endpoints such as time to recovery or clinical status. These issues
260 represent some factors that led to the selection of the primary endpoint in this study. Secondly,
261 this study was performed in the pre-omicron era. However, despite changes in the predominant
262 circulating variant over time and decreased disease severity overall, we continue to see patients
263 admitted to hospital with respiratory failure and evidence of immune dysregulation. Finally, while
264 there is a theoretical concern that a shared control group could negatively impact multiple
265 treatment evaluations in a platform study such as this, an examination of baseline
266 characteristics does not indicate this issue for ACTIV-1 IM. Integrity of the comparative analyses
267 was preserved through inclusion of only those participants in the shared placebo group who
268 were eligible to receive infliximab, and through the requirement that placebo participants were
269 shared only among agents active in the master protocol at the same time. More importantly, the
270 use of a shared control group has significant practical and ethical benefits.²¹

271 This report from ACTIV-1 IM shows that infliximab added to standard of care was
272 associated with clinically meaningful improvements in a number of key secondary outcomes,
273 including a 4% absolute reduction in 28-day mortality. As SARS-CoV-2 moves from being
274 pandemic to endemic, and while new variants continue to emerge, ongoing morbidity and

275 mortality from this disease is likely. Expanding our treatment toolbox and developing optimized
276 treatment strategies remains paramount.

277

278 **Author Information**

279 Jane A. O'Halloran, MD, PhD, Eyal Kedar, MD, Kevin J. Anstrom, PhD, Matthew W. McCarthy,
280 MD, Emily Ko, MD, PhD, Patricia Segura Nunez, MD, Cynthia Boucher, MS, P. Brian Smith,
281 MD, MPH, MHS, Reynold A. Panettieri, Jr, MD, Sabina Mendivil Tuchia de Tai, MD, Martin
282 Maillo, MD, Akram Khan, MD, Alfredo J. Mena Lora, MD, Matthias Salathe, MD, Gerardo Capo,
283 MD, Daniel Rodríguez Gonzalez, MD, Thomas F Patterson, MD, Christopher Palma, MD, ScM,
284 Horacio Ariza, MD, Maria Patelli Lima, MD, Anne M. Lachiewicz, MD, John Blamoun, MD,
285 Esteban C. Nannini, MD, Eduardo Sprinz, MD, Analia Mykietiuk, MD, Radica Alicic, Adriana M.
286 Rauseo, MD, Cameron R. Wolfe, MBBS, MPH, Britta Witting, Daniel K. Benjamin, Jr, MD, MPH,
287 PhD, Steven E. McNulty, MS, Pearl Zakrofsky, S. Halabi, PhD, Sandra Butler, PhD, Jane
288 Atkinson, DDS, Stacey J. Adam, PhD, Richard Melsheimer, Soju Chang, MD, MPH, Lisa
289 LaVange, PhD, Michael Proschan, PhD, Samuel A. Bozzette, MD, PhD, William G. Powderly,
290 MD

291

292 Washington University St. Louis, St Louis, MO (J.A.O., A.R.A., W.G.P.); Weill Cornell Medicine
293 in New York (M.W.M., B.W.), University of North Carolina, Chapel Hill, NC (K.J.A., L.L., A.M.L.);
294 St. Lawrence Health, Potsdam, NY. (E.K.); Duke University Medical Center, Durham, NC (E.K.,
295 C.R.W.), Hospital Nacional Hipolito Unanue, Lima, Peru (P.S.N); National Center for Advancing
296 Translational Sciences (C.B., S.C., J.A., S.A.B.); Duke Clinical Research Institute (DCRI)
297 (D.K.B., P.B.S., P.Z., S.M., S.H.), Robert Wood Johnson Medical School, New Brunswick, NJ
298 (R.A.P.); Hospital Central de la Fuerza Aerea del Peru, Lima, Peru (S.M.T.T.); Sanatorio
299 Diagnostico, Santa Fe, Argentina (M.M.); Oregon Health and Science University, Portland, OR
300 (A.K.); University of Illinois at Chicago, Chicago, IL (A.M.L.); University of Kansas Medical

301 Center, Kansas City, KS (M.S.); Trinitas Hospital, Elizabeth, NY (G.C.); Nuevo Hospital Civil de
302 Guadalajara Juan I. Menchaca, Guadalajara, Mexico (D.R.G.); University of Texas Health
303 Science Center at San Antonio, San Antonio, TX (T.F.P.); University of Rochester School of
304 Medicine and Dentistry, Rochester, NY (C.P.); Clinica Central S.A., Villa Regina, Argentina
305 (H.A.); Hospital e Maternidade Celso Pierro - PUC Campinas, Campinas, Brazil (M.P.L.);
306 MidMichigan Medical Center – Midland, Midland, MI (J.B.); Sanatorio Britanico. Santa Fe,
307 Argentina (E.C.N.); Hospital de Clinicas de Porto Alegre HCPA, Porto Alegre, Brazil (E.S.);
308 Instituto Medico Platense, La Plata, Argentina (A.M.); Providence Medical Research Center,
309 Spokane, WA (R.A.); Technical Resources International (TRI), Bethesda MD (SB); Foundation
310 for the National Institutes of Health (FNIH) (S.J.A.); Janssen Pharmaceuticals (R.M), National
311 Institute of Allergy and Infectious Diseases (NIAID) (M.P.).

312

313 **Acknowledgements**

314 We thank the members of the ACTIV-1 Study Team (see Supplementary Appendix) for their
315 many contributions in conducting the trial, the members of the data and safety monitoring board,
316 William Blackwelder, PhD (chair) (University of Maryland School of Medicine, Baltimore, MD),
317 Timothy G. Buchman, PhD, MD (Emory University School of Medicine, Atlanta, GA), Wilbur H.
318 Chen, MD, MS (University of Maryland School of Medicine, Center for Vaccine Development
319 and Global Health, Baltimore, MD), Lawrence H. Moulton, PhD (Johns Hopkins University,
320 Bloomberg School of Public Health, Baltimore, MD), David M. Parenti, MD (The George
321 Washington University School of Medicine, Washington, DC), Carol O. Tacket, MD (University
322 of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore,
323 MD), William Checkley, MD, PhD (Johns Hopkins University, Baltimore, MD), and Beatriz
324 Grinsztejn, MD (Instituto Nacional de Infectologia Evandro Chagas-Fiocruz, Rio de Janeiro,
325 Brazil) for their oversight; the Community Advisory Board, Larisa Caicedo, Ashish Cowlagi,

326 Anna Davis, Lincoln Larmond, Doug Lindsey, Bob Pearson and the patients and their families
327 for their altruism in participating in this trial.

328

329 **Funding**

330 This project has been funded with federal funds from the U.S. Department of Health and Human
331 Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical
332 Advanced Research and Development Authority, under contract number
333 HHSO100201400002I/75A50120F33002. The findings and conclusions in this publication are
334 those of the authors and do not necessarily represent the views of the Department of Health
335 and Human Services or its components. Janssen provided infliximab for use in this trial but did
336 not provide any financial support. Gilead Sciences provided remdesivir for use in this trial but
337 did not provide any financial support. Employees of Janssen and Gilead Sciences participated
338 in discussions about protocol development and in weekly protocol team calls. The final trial
339 protocol was developed by the protocol chair, Dr. William Powderly, the IND sponsor Dr. Daniel
340 K. Benjamin, Jr, and a protocol development committee including representatives from the
341 National Center for Advancing Translational Sciences (NCATS). NCATS had a collaborative
342 role in the trial design, management, interpretation of the data and the preparation of the
343 manuscript along with the protocol chair, the study statisticians and the study writing group.

344

345 Infrastructure support and resources for research reported in this publication were provided in
346 part by NCATS of the National Institutes of Health under award number(s):UL1TR002345 to
347 Washington University in St. Louis; the Duke University – Vanderbilt University Medical Center
348 Trial Innovation Center (U24TR001608) (NCATS, Trial Innovation Network).

349

350 **Data Sharing**

351 A data sharing statement provided by the authors is available with this article.

352 **REFERENCES**

- 353 1. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for
354 monocytes and macrophages. *Nat Rev Immunol* 2020;20:355-62.
- 355 2. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to
356 Severe Covid-19 in Outpatients. *N Engl J Med* 2022;386:305-15.
- 357 3. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-
358 19. *N Engl J Med* 2021;384:693-704.
- 359 4. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a
360 randomised, controlled, open-label, platform trial. *Lancet* 2021;397:1637-45.
- 361 5. Gordon AC, Angus DC, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill
362 Patients with Covid-19. Reply. *N Engl J Med* 2021;385:1147-9.
- 363 6. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the
364 treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-
365 blind, parallel-group, placebo-controlled phase 3 trial. *Lancet Respir Med* 2021;9:1407-
366 18.
- 367 7. Feldmann M, Maini RN, Woody JN, et al. Trials of anti-tumour necrosis factor therapy for
368 COVID-19 are urgently needed. *Lancet* 2020;395:1407-9.
- 369 8. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature
370 predicts COVID-19 severity and survival. *Nat Med* 2020;26:1636-43.
- 371 9. Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the
372 severity of virus-specific lung immunopathology. *Eur J Immunol* 2001;31:2566-73.
- 373 10. Hachem H, Godara A, Schroeder C, et al. Rapid and sustained decline in CXCL-10 (IP-
374 10) annotates clinical outcomes following TNFalpha-antagonist therapy in hospitalized
375 patients with severe and critical COVID-19 respiratory failure. *J Clin Transl Sci*
376 2021;5:e146.

- 377 11. Fisher BA, Veenith T, Slade D, et al. Namilumab or infliximab compared with standard of
378 care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre,
379 multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial. *Lancet*
380 *Respir Med* 2022;10:255-66.
- 381 12. Dolinger MT, Person H, Smith R, et al. Pediatric Crohn Disease and Multisystem
382 Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab. *J*
383 *Pediatr Gastroenterol Nutr* 2020;71:153-5.
- 384 13. Brenner EJ, Ungaro RC, Geary RB, et al. Corticosteroids, But Not TNF Antagonists, Are
385 Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel
386 Diseases: Results From an International Registry. *Gastroenterology* 2020;159:481-91
387 e3.
- 388 14. Melong Pianta Taleng CM, Lauper K, Gilbert B, et al. Incidence of COVID-19 in patients
389 treated with infliximab compared with patients treated with rituximab. *RMD Open* 2021;7.
- 390 15. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing
391 Risk. *J Am Stat Assoc* 1999;94:496-509.
- 392 16. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus Remdesivir for Hospitalized
393 Adults with Covid-19. *N Engl J Med* 2021;384:795-807.
- 394 17. Investigators R-C, Gordon AC, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in
395 Critically Ill Patients with Covid-19. *N Engl J Med* 2021;384:1491-502.
- 396 18. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19)
397 Treatment Guidelines. National Institutes of Health. Available at
398 <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [8/21/2022].
- 399 19. Guo Y, Hu K, Li Y, et al. Targeting TNF-alpha for COVID-19: Recent Advanced and
400 Controversies. *Front Public Health* 2022;10:833967.
- 401 20. Douin DJ, Siegel L, Grandits G, et al. Evaluating Primary Endpoints for COVID-19
402 Therapeutic Trials to Assess Recovery. *Am J Respir Crit Care Med* 2022.

- 403 21. LaVange L, Adam SJ, Currier JS, et al. Accelerating COVID-19 Therapeutic
404 Interventions and Vaccines (ACTIV): Designing Master Protocols for Evaluation of
405 Candidate COVID-19 Therapeutics. *Ann Intern Med* 2021;174:1293-300.
406
407

408 **Figure Legends**

409 **Figure 1.** Forest plot of 28-day mortality by subgroup (modified intent-to-treat population)

410 **Figure 2.** Kaplan-Meier curves of cumulative incidence of overall mortality at (A) day 28, (B) day

411 60, and by illness severity by ordinal scale for (C) mechanical ventilation or ECMO, (D) high-

412 flow oxygen devices or non-invasive ventilation, and (E) low-flow supplemental oxygen.

413

414 **Table 1. Demographics and baseline characteristics (modified intent-to-treat)**

	Infliximab	Shared Placebo	Total
Demographics and baseline characteristics	(N=517)	(N=516)	(N=1033)
Age, mean (SD), yrs	54.7 (14.94)	54.9 (14.65)	54.8 (14.79)
Male sex, no. (%)	325 (62.9%)	298 (57.8%)	623 (60.3%)
Race, no. (%)			
White	319 (61.7%)	333 (64.5%)	652 (63.1%)
Black or African American	77 (14.9%)	68 (13.2%)	145 (14.0%)
American Indian or Alaska Native	5 (1.0%)	4 (0.8%)	9 (0.9%)
Asian	11 (2.1%)	16 (3.1%)	27 (2.6%)
Native Hawaiian or Other Pacific Islander	1 (0.2%)	0 (0.0%)	1 (0.1%)
Multiracial	2 (0.4%)	2 (0.4%)	4 (0.4%)
Other	76 (14.7%)	71 (13.8%)	147 (14.2%)
Unknown	26 (5.0%)	22 (4.3%)	48 (4.6%)
Hispanic or Latino ethnicity, no. (%)	252 (48.7%)	250 (48.4%)	502 (48.6%)
Disease severity at baseline*, no. (%)			
Severe disease	228 (44.1%)	227 (44.0%)	455 (44.0%)
Moderate disease	289 (55.9%)	289 (56.0%)	578 (56.0%)
Clinical status (8-point ordinal scale) at baseline, no. (%)			
1. Death	0	0	0

2. Hospitalized, on invasive ventilation or ECMO	58 (11.2%)	53 (10.3%)	111 (10.7%)
3. Hospitalized, on non-invasive ventilation or high flow oxygen devices	170 (32.9%)	174 (33.7%)	344 (33.3%)
4. Hospitalized, requiring supplemental oxygen	268 (51.8%)	270 (52.3%)	538 (52.1%)
5. Hospitalized, not requiring supplement oxygen, requiring ongoing medical care	21 (4.1%)	19 (3.7%)	40 (3.9%)
6. Hospitalized, not requiring supplement oxygen, not requiring ongoing medical care	0	0	0
7. Not hospitalized, limitations on activity and/or requiring home oxygen	0	0	0
8. Not hospitalized, no limitations on activities	0	0	0
Geographic region, no. (%)			
Argentina	56 (10.8%)	59 (11.4%)	115 (11.1%)
Brazil	54 (10.4%)	54 (10.5%)	108 (10.5%)
Mexico	15 (2.9%)	16 (3.1%)	31 (3.0%)
Peru	62 (12.0%)	56 (10.9%)	118 (11.4%)
USA - Northeast	119 (23.0%)	118 (22.9%)	237 (22.9%)
USA - Midwest	81 (15.7%)	77 (14.9%)	158 (15.3%)
USA - South	93 (18.0%)	94 (18.2%)	187 (18.1%)
USA - West	37 (7.2%)	42 (8.1%)	79 (7.6%)
Days from symptom onset, mean (SD)	-9.9 (4.41)	-9.9 (5.61)	-9.9 (5.04)
BMI, mean (SD), kg/m ²	32.1 (7.97)	32.7 (8.11)	32.4 (8.04)

Comorbidities, no. (%)

Hypertension	207 (40.0%)	209 (40.5%)	416 (40.3%)
Obesity (BMI \geq 30 kg/m ²)	268 / 507 (52.9%)	299 / 502 (59.6%)	567 / 1009 (56.2%)
Diabetes mellitus	138 (26.7%)	144 (27.9%)	282 (27.3%)
Coronary artery disease	38 (7.4%)	27 (5.2%)	65 (6.3%)
History of heart failure	16 (3.1%)	14 (2.7%)	30 (2.9%)
History of cancer	34 (6.6%)	34 (6.6%)	68 (6.6%)
Asthma	35 (6.8%)	53 (10.3%)	88 (8.5%)
Chronic obstructive pulmonary disease	24 (4.6%)	26 (5.0%)	50 (4.8%)
Tuberculosis	3 (0.6%)	4 (0.8%)	7 (0.7%)
HIV/AIDS	2 (0.4%)	4 (0.8%)	6 (0.6%)
Severe liver disease	3 (0.6%)	2 (0.4%)	5 (0.5%)
Severe kidney disease	3 (0.6%)	7 (1.4%)	10 (1.0%)

Concomitant medication, no. (%)

Remdesivir (Day 1 - Day 5)	486 (94.0%)	489 (94.8%)	975 (94.4%)
Corticosteroids (Day 1 - Day 5)	468 (90.5%)	482 (93.4%)	950 (92.0%)
Tocilizumab (any time post randomization)	7 (1.4%)	12 (2.3%)	19 (1.8%)
Baricitinib (any time post randomization)	5 (1.0%)	11 (2.1%)	16 (1.5%)

415 BMI indicates body mass index; ECMO, extracorporeal membrane oxygenation; SD, standard deviation; USA, United States of America.

416 *Disease severity at baseline calculated as moderate disease = ordinal 5 + ordinal 4, severe disease = ordinal 3 + ordinal 2

417

418 **Table 2. Primary and Key Secondary Endpoints (Modified Intent-to-Treat Population)**

	Infliximab	Shared Placebo	Infliximab versus Shared Placebo	
	Proportion of Participants		Estimate (95% CI)	p value
Recovery through Day 28				
Overall	416/517 (80.5%)	398/516 (77.1%)	1.130 (0.993, 1.286)	0.0631
Baseline 8-point ordinal scale				
2. Hospitalized, on invasive ventilation or ECMO	24/58 (41.4%)	20/53 (37.7%)	1.117 (0.612, 2.039)	
3. Hospitalized, on non-invasive ventilation or high flow oxygen devices	124/170 (72.9%)	111/174 (63.8%)	1.326 (1.039, 1.693)	
4. Hospitalized, requiring supplemental oxygen	247/268 (92.2%)	248/270 (91.9%)	1.090 (0.923, 1.286)	
5. Hospitalized, not requiring supplement oxygen, requiring ongoing medical care	21/21 (100.0%)	19/19 (100.0%)	0.767 (0.404, 1.455)	
Baseline C-reactive protein				
≤ 75 mg/L	187/216 (86.6%)	182/210 (86.7%)	1.018 (0.829, 1.250)	
> 75 mg/L	171/228 (75.0%)	147/209 (70.3%)	1.203 (0.974, 1.486)	
Mortality at Day 28[†]				
Overall	52/517 (10.1%)	75/516 (14.5%)	0.593 (0.390, 0.904)	
Baseline 8-point ordinal scale				
2. Hospitalized, on invasive ventilation or ECMO	18/58 (31.0%)	16/53 (30.2%)	1.106 (0.449, 2.723)	
3. Hospitalized, on non-invasive ventilation or high	26/170 (15.3%)	43/174 (24.7%)	0.516 (0.291, 0.914)	

flow oxygen devices			
4 or 5: Hospitalized, with or without supplemental oxygen, requiring ongoing medical care [‡]	8/289 (2.8%)	16/289 (5.5%)	0.470 (0.195, 1.131)
Baseline C-reactive protein			
≤ 75 mg/L	19/216 (8.8%)	18/210 (8.6%)	0.788 (0.372, 1.668)
> 75 mg/L	28/228 (12.3%)	42/209 (20.1%)	0.551 (0.304, 0.996)
Clinical status at Day 14 (N)[§]			
Overall	502	501	1.318 (1.047, 1.659)
Baseline 8-point ordinal scale			
2. Hospitalized, on invasive ventilation or ECMO	58	53	1.284 (0.655, 2.519)
3. Hospitalized, on non-invasive ventilation or high flow oxygen devices	165	169	1.477 (1.008, 2.165)
4. Hospitalized, requiring supplemental oxygen	258	261	1.260 (0.914, 1.737)
5. Hospitalized, not requiring supplement oxygen, requiring ongoing medical care	21	18	0.972 (0.367, 1.090)
Mortality at Day 60	65/517 (12.6%)	85/516 (16.5%)	0.679 (0.461, 0.999)

419 *Time to recovery calculated as recovery rate ratio using stratified Fine-Gray model. A number greater than 1 favors Infliximab.
420 †Mortality at 28 days calculated as odds of dying using logistic regression. A number less than 1 favors Infliximab.
421 ‡No deaths were reported for baseline 8-point ordinal scale 5. Baseline 8-point ordinal scale values 4 and 5 were combined to address modeling issues.
422 §Clinical status at 14 days calculated as proportional odds model by ordinal logistic regression. A number greater than 1 favors Infliximab.
423 CI indicates confidence interval; ECMO, extracorporeal membrane oxygenation.
424
425

Table 3. Safety composite and adverse events through day 60

Safety Composite and Adverse Events	Shared		Total (N=1033)	Risk Difference (95% CI)
	Infliximab (N=517)	Placebo (N=516)		
Safety Composite*	170 (32.9%)	174 (33.7%)	344 (33.3%)	-0.8 (-6.6, 4.9)
SAE	125 (24.2%)	130 (25.2%)	255 (24.7%)	-1.0 (-6.3, 4.2)
Grade 3 or 4 AE	146 (28.2%)	131 (25.4%)	277 (26.8%)	2.9 (-2.6, 8.3)
Grade 4 AE	63 (12.2%)	64 (12.4%)	127 (12.3%)	-0.2 (-4.3, 3.8)
Grade 3 AE	124 (24.0%)	97 (18.8%)	221 (21.4%)	5.2 (0.2, 10.2)
Secondary Infections				
Any Secondary Infection/Superinfection	79 (15.3%)	72 (14.0%)	151 (14.6%)	
Confirmed	24 (4.6%)	26 (5.0%)	50 (4.8%)	
Probable	55 (10.6%)	46 (8.9%)	101 (9.8%)	
Any Bacterial	71 (13.7%)	55 (10.7%)	126 (12.2%)	
Bacterial Pneumonia	49 (9.5%)	36 (7.0%)	85 (8.2%)	
Bloodstream infections	17 (3.3%)	15 (2.9%)	32 (3.1%)	
Urinary tract infections	15 (2.9%)	16 (3.1%)	31 (3.0%)	
Other bacterial infections	6 (1.2%)	2 (0.4%)	8 (0.8%)	
Tuberculosis	1 (0.2%)	0 (0.0%)	1 (0.1%)	
Any Fungal	14 (2.7%)	23 (4.5%)	37 (3.6%)	


Oral/oropharyngeal candidiasis	5 (1.0%)	8 (1.6%)	13 (1.3%)
Invasive candidiasis	4 (0.8%)	5 (1.0%)	9 (0.9%)
Other fungi infections	3 (0.6%)	8 (1.6%)	11 (1.1%)
Mold Infection (Aspergillus species, mucormycosis and other)	2 (0.4%)	2 (0.4%)	4 (0.4%)
Any Viral	2 (0.4%)	2 (0.4%)	4 (0.4%)

*The safety composite endpoint includes any of the following events: deaths, SAEs and Grade 3 or 4 AEs through Day 60.
 AE indicates adverse event: CI, confidence interval; SAE, serious adverse event.

427
 428
 429
 430

431 **Figure 1.**


**Forest Plot of 28-Day Mortality by Subgroup
Modified Intent-to-Treat Population**



432


433

434 **Figure 2A.**



435

436 **Figure 2B.**




437

438

439 **Figure 2C.**

**Cumulative Incidence of Time to Death through Day 28 - Baseline 8-point Ordinal Scale = 2
Modified Intent-to-Treat Population**




440

441

442 **Figure 2D.**

**Cumulative Incidence of Time to Death through Day 28 - Baseline 8-point Ordinal Scale = 3
Modified Intent-to-Treat Population**




443

444

445 **Figure 2E.**

**Cumulative Incidence of Time to Death through Day 28 - Baseline 8-point Ordinal Scale = 4
Modified Intent-to-Treat Population**



446